The trend of labelling changes continues for the third consecutive year, and the FDA’s recent removal of boxed warning labels for hormone replacement therapy may provide some clues as to why. Filed under USA Company & Commercial Healthcare & Life Sciences Product Regulation & Liability Topics Approved drug Data Data analysis Generic drug Labelling Pharmaceuticals Product safety Organisations US Department of Health and Human Services US Food and Drug Administration Moderna Pfizer Industries Pharmaceuticals Pharmaceuticals & chemicals
